Accelerated apoptosis and low bcl-2 expression associated with neuroendocrine differentiation predict shortened survival in operated large cell carcinoma of the lung

Pathology and Oncology Research

Volumn 5, Issue 3, 1999, Pages 179-186

  Eerola, Anna Kaisa ^b   Ruokolainen, Henni ^b   Soini, Ylermi ^a,b   Raunio, Hannu ^a   Pääkkö, Paavo ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bak; Bax; Mcl 1; Neuroendocrine differentiation; Prognosis

Indexed keywords

DNA; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG CARCINOMA; NEUROENDOCRINE TUMOR; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0032752014     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1053/paor.1999.0198     Document Type: Article

References (43)

1. Aihara M, Truong I D, Dunn J K. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol. 25:1994;797-801.
2. Basolo F, Pollina L, Fontanini G. Apoptosis and proliferation in thyroid carcinoma: correlation with bcl-2 and p53 protein expression. Br J Cancer. 75:1997;537-541.
3. Brambilla E, Negoescu A, Gazzeri S. Apoptosis-related factors p53, bcl2 and bax in neuroendocrine lung tumors. Am J Pathol. 149:1996;1941-1952.
4. Chittenden T, Harrington E A, O'Connor R. Induction of apoptosis by the bcl-2 homologue bak. Nature. 374:1995;733-736.
5. Downey R S, Sewell W, Mansour K A. Large cell carcinoma of the lung: a highly aggressive tumor with dismal prognosis. Ann Thorac Surg. 47:1989;806-808.
6. Eerola A K, Törmänen U, Rainio P. Apoptosis in operated small cell lung carcinoma is inversely related to tumor necrosis and p53 immunoreactivity. J Pathol. 181:1997;172-177.
7. Fleming M V, Guinee D G, Chu W S. Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol. 29:1998;60-64.
8. Fontanini G, Vignati S, Bigini D. Bcl2 protein: a prognostic factor inversely correlated to p53 in non-small cell lung cancer. Br J Cancer. 71:1995;1003-1007.
9. Hellquist H B, Olejnicka B, Jadner M. Fas receptor is expressed in human lung squamous cell carcinomas, whereas bcl-2 and apoptosis are not pronounced. Br J Cancer. 76:1997;175-179.
10. Ikegaki N, Katsumata M, Minna J. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 54:1994;6-8.
11. Jiang S X, Kameya T, Sato Y. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am J Pathol. 148:1996;837-846.
12. Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 45:1994;1191-1198.
13. Kiefer M C, Brauer M J, Powers V C. Modulation of apoptosis by the widely distributed bcl-2 homologue bak. Nature. 374:1995;736-739.
14. King E D, Matteson J, Jacobs S C, Kyprianou N. Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J Urol. 155:1996;316-320.
15. Krajewska M, Krajewski S, Epstein J I. Immunohistochemical analysis of bcl-2, bax, bcl-x and mcl-1 expression in prostate cancers. Am J Pathol. 148:1996;1567-1576.
16. Kroemer G. The proto-oncogene bcl-2 and its role in regulating apoptosis. (Review). Nature Med. 3:1997;614-620.
17. Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage Y4. Nature. 227:1970;680-685.
18. Lipponen P K, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 173:1994;333-339.
19. Longthorne V L, Williams G T. Caspase activity is required for commitment to Fas-mediated apoptosis. EMBO J. 16:1997;3805-3812.
20. Mustonen M, Raunio H, Pääkkö P. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology. 31:1997;347-354.
21. Niehans G A, Brunner T, Frizelle S P. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
22. Oltvai Z N, Milliman C L, Korsmeyer S J. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
23. Pezzella F, Turley H, Kuzu I. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med. 329:1993;690-694.
24. Pääkkö P, Sormunen R, Risteli L. Malotilate prevents accumulation of type III pN-collagen, type IV collagen, and laminin in carbon tetrachloride-induced pulmonary fibrosis in rats. Am Rev Respir Dis. 139:1989;1105-1111.
25. Rampino N, Yamamoto H, Ionov Y. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science. 275:1997;967-969.
26. Reed J C. Bcl-2 and regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
27. Reed J C, Meister L, Tanaka S. Differential expression of bcl-2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Res. 15:1991;6529-6538.
28. Sato T, Hanada M, Bodrug S. Interactions among members of the bcl-2 protein family analyzed by two-hybrid system. Proc Natl Acad Sci USA. 91:1994;9238-9242.
29. Segal N H, Cohen R J, Haffejee Z. Bcl-2 proto-oncogene expression in the prostatic neuroendocrine cell. Arch Pathol Lab Med. 118:1994;616-618.
30. Silvestrini R, Veneroni S, Daidone M G. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 86:1994;499-504.
31. Soini Y, Pääkkö P, Lehto V P. Histopathological evaluation of apoptosis in cancer. (Review). Am J Pathol. 153:1998;1041-1053.
32. Soini Y, Törmänen U, Pääkkö P. Apoptosis is inversely related to bcl-2 but not to bax expression in salivary gland tumors. Histopathology. 32:1998;28-34.
33. Soini Y, Virkajärvi N, Lehto V P. Hepatocellular carcinomas with a high proliferation index and a low degree of apoptosis and necrosis are associated with a shortened survival. Br J Cancer. 73:1996;1025-1030.
34. Stammler G, Volm M. Apoptosis in non-small cell lung cancer as related to drug resistance and prognosis. Apoptosis. 1:1996;95-99.
35. Staunton M J, Gaffney E F. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol. 103:1995;300-307.
36. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA. 76:1979;4350-4354.
37. Travis W D, Linnoila I, Tsokos M G. Neuroendocrine tumors of the lung with proposed criteria for large cell neuroendocrine carcinoma. Am J Surg Pathol. 15:1991;529-553.
38. Travis W D, Rush W, Flieder D B. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 22:1998;934-944.
39. Törmänen U, Eerola A K, Rainio P. Enhanced apoptosis predicts shortened survival in non-small cell lung carcinoma. Cancer Res. 55:1995;5595-5602.
40. Virkajärvi N, Pääkkö P, Soini Y. Associaton between p53 overexpression, cell proliferation, tumor necrosis and extent of apoptosis in operated pancreatic carcinoma. APMIS. 105:1997;765-772.
41. Wang D G, Johnston C F, Sloan J M. Expression of bcl-2 in lung neuroendocrine tumors: comparison with p53. J Pathol. 184:1998;247-251.
42. WHO. Histological Typing of Lung Tumors. International Classification of Tumors. 2nd edn. 1981;World Health Organization, Geneva.
43. Yin X M, Oltvai Z N, Korsmeyer S J. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature. 369:1994;321-323.